Morris continued - Organ savings SQI builds for these practitioners by anticipating and meeting the needs of those who bear these excellent qualities. That’s what we’re doing with our EXACT Antibody Test and with our RALI-Dx or rapid acute lung injury diagnostic test. We’re creating data that helps doctors make better decisions for their patients and families.
The same can be said with our TORdx test, which converts transplant doctors from solely relying on the qualitative decision-making tools that they’ve developed over their careers and provides them with a quantitative measurement of the health of a donor lung. We want to apply this same technology across multiple organs. The TORdx test is disruptive and meets an unmet need by providing information based on broader datasets as opposed to individual spot tests used before individual lung transplants. We found, after looking at the big data, that a lot of lungs were being discarded using mostly qualitative assessments by transplant surgeons and we found that about half of those discarded lungs were actually quantitatively similar to viable lungs.
Providers looking to improve care have a tool to help them rebalance the supply-demand curve and get lungs into patients earlier in their disease stages. They’re healthier when they get their transplanted lung, their time in the ICU is shortened, and the recovery time is shortened and the cost to the health care system is, in theory, reduced.
Disruptive technologies require health care providers to adopt new ways of doing things, and that’s not always the easiest. However, in order to deliver the highest quality care, an excellent provider will follow science and data and is open to innovation when the data shows that a potential therapy or diagnostic product is really addressing an unmet need.